Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Nutex Health (NUTX) EBITDA (2016 - 2025)

Nutex Health's EBITDA history spans 16 years, with the latest figure at $39.4 million for Q4 2025.

  • For Q4 2025, EBITDA fell 65.55% year-over-year to $39.4 million; the TTM value through Dec 2025 reached $275.6 million, up 110.89%, while the annual FY2025 figure was $275.6 million, 110.89% up from the prior year.
  • EBITDA for Q4 2025 was $39.4 million at Nutex Health, down from $130.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $137.7 million in Q3 2021 and bottomed at -$428.7 million in Q3 2022.
  • The 5-year median for EBITDA is $4.9 million (2022), against an average of $693724.6.
  • The largest annual shift saw EBITDA surged 7651.96% in 2021 before it tumbled 674.28% in 2023.
  • A 5-year view of EBITDA shows it stood at -$119.1 million in 2021, then skyrocketed by 103.82% to $4.6 million in 2022, then crashed by 674.28% to -$26.1 million in 2023, then surged by 537.13% to $114.3 million in 2024, then tumbled by 65.55% to $39.4 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's EBITDA are $39.4 million (Q4 2025), $130.4 million (Q3 2025), and $33.7 million (Q2 2025).